Payer+Provider's Health System Review
Activist investor says Cerner can grow margins 9% in next 18 months
FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering.
April 17, 2019
Coughlin JM, Shallcross ML, Schäfer WLA, et al. J Surg Res. 2019;239:309-319.
Read the full post on AHRQ PSNet